Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock

NEXT STORY
Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer
PREV STORY
Afya Limited Announces First Quarter 2020 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Point-of-Care Testing Market Analysis and Forecast Report 2018: Market was Estimated at $13.87 Bn in 2017 and is Estimated to Grow Over $23.92 Bn by 2026

author_avatar
NASDAQ Market News

Corvus Pharmaceuticals Announces New Data on Adenosine Gene Signature Biomarker Associated with Patient Response to CPI-444 at European Society for Medical Oncology (ESMO) 2018 Congress

Predictive biomarker can potentially identify patients most likely to benefit from CPI-444 and other ...

author_avatar
NASDAQ Market News

Beta Bionics Announces Start of Home-Use Clinical Trials with the iLet™ Bionic Pancreas System and Receives IDE Approval from the FDA to Expand its Clinical Trials to Include the Senseonics Eversense CGM Integrated into the iLet

The Beta Bionics iLet Bionic Pancreas System is now approved for clinical trials in ...

author_avatar
NASDAQ Market News